Thermo Fisher Scientific (TMO) Total Current Liabilities (2009 - 2026)

Thermo Fisher Scientific has disclosed Total Current Liabilities across 18 years of filings, most recently posting $14.6 billion for Q1 2026.

• Quarterly Total Current Liabilities rose 10.98% year-over-year to $14.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 billion (up 10.98% YoY) and the FY2025 annual result came in at $15.2 billion, up 13.93% from the prior year.
• Total Current Liabilities eased to $14.6 billion in Q1 2026, from $15.2 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $17.0 billion in Q4 2022 and troughed at $11.0 billion in Q3 2022.
• A 5-year average of $13.9 billion and a median of $14.1 billion in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 72.55% — and 2023, when it slipped 17.62%.
• Tracing TMO's Total Current Liabilities over 5 years: stood at $17.0 billion in 2022, then fell by 17.62% to $14.0 billion in 2023, then decreased by 4.85% to $13.3 billion in 2024, then rose by 13.93% to $15.2 billion in 2025, then decreased by 3.74% to $14.6 billion in 2026.
• Business Quant data shows TMO's Total Current Liabilities at $14.6 billion in Q1 2026, $15.2 billion in Q4 2025, and $14.9 billion in Q3 2025.